-
Hello Kitty firm apologises, scraps Japan TV tie-up after China anger
-
TotalEnergies profit hits record on high oil prices
-
Taiwan says Pakistan briefly closed airspace to Taiwanese flights
-
Key of seethe: I.Coast row with Sahel juntas spills into concert halls
-
'My blood was spilled here': a year on, Tanzania unable to mourn election violence
-
Romanian writer Cartarescu hails books as balm in turmoil
-
Afghanistan opium poppy cultivation surges despite Taliban govt ban: UN
-
Mbappe, Real Madrid and La Liga face long road to redemption in China
-
No World Series miracle for weary Rays
-
North Korea fires 'around a dozen' ballistic missiles into East Sea
-
Miami Heat earn first win of NBA season with Antetokounmpo
-
Brewers catcher Contreras named World Series MVP
-
Brewers beat Rays 4-1 to capture first World Series title
-
Asian stock markets fluctuate after mixed tech results
-
Philippine island fights rising seas with nature, not concrete
-
Samsung logs record quarterly profits despite investor AI jitters
-
Bangladesh presses India before Ganges water treaty expires
-
Miami stumble to draw against Cincinnati despite Suarez strike
-
Trump accuses Alaska Democrats of fraud over same-name scandal
-
Bangladesh scrambling as Ganges water treaty to expire
-
Spain mourns after latest train tragedy kills 68
-
England in peril with Rugby League World Cup semi spots at stake
-
Trump's border: quiet, but few people are happy
-
Antonelli ready to rewrite the Formula One record books in Mexico
-
Australian defence chief says China military buildup creating 'pressure' in SE Asia
-
EU, Canada to build 'new chapter' in alliance at Montreal summit
-
No penalty practice? No problem for Man City in shoot-out win
-
Argentine football fan jailed for threats over Di Maria return
-
Microsoft beats expectations fueled by Azure cloud business
-
Liverpool beat Chelsea in League Cup shoot-out, Man City survive scare
-
Chelsea win as Bayern draw with Madrid in Women's Champions League
-
Inter leave it late again in Serie A as AC Milan, Juventus lose
-
Kane watches as Bayern cruise into German Cup last 16
-
Shares in Google owner Alphabet plummet on profit miss, ad slowdown
-
Bayern boss Kompany out of hospital after meningeal irritation
-
Putin hails Elon Musk as 'truly a genius'
-
Shares in Google owner Alphabet sink on profit miss, ad slowdown
-
US stocks eye big tech earnings as Fed holds rates steady
-
Chelsea win as Bayern and Madrid draw in Women's Champions League
-
US Fed holds interest rates steady despite 'too high' inflation
-
Made with munitions from the Falklands War, a 'Chalice of Peace' for the pope
-
Rwanda cannot be blamed for what happens in DR Congo, FM says
-
Pioneering US labor leader Dolores Huerta dies at 96
-
Inter leave it late again in Serie A as Bologna sink AC Milan
-
Italian PM slams 'shameful' release of alleged protest organiser
-
Bolsonaro's escape to the US: How it happened
-
Hollywood producer Kennedy to head LA28 Olympic ceremony plans
-
Russell calls on Scotland to 'kick on' and beat big teams
-
Djokovic wins Basel opener to boost ATP Finals bid
-
Airbus aims for record deliveries despite disappointing quarter
The scientist rewriting DNA, and the future of medicine
A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented precision.
A professor at the Broad Institute of MIT and Harvard, Liu was awarded a Breakthrough Prize in Life Sciences on Saturday for developing two transformative technologies: one already improving the lives of patients with severe genetic diseases, the other poised to reshape medicine in the years ahead.
He spoke with AFP ahead of the Los Angeles ceremony for the prestigious Silicon Valley-founded award.
He will receive $3 million for his work on "base editing" and "prime editing," and plans to donate most of it to support his charitable foundation.
"The ability to change a DNA sequence of our choosing into a new sequence of our choosing is a fundamentally very powerful capability," the 51-year-old said, foreseeing uses not just in human medicine but areas like developing more nutritious or disease-resistant crops.
- Correcting the code -
DNA is made up of four chemical "letters" -- the nucleotide bases A, G, T and C. Mutations in this sequence cause thousands of human diseases, yet until recently, gene editing could only fix a limited number of them.
Even CRISPR-Cas9, the groundbreaking technology that earned a Nobel Prize in 2020, has major limitations.
It cuts both strands of the DNA helix, making it most useful to disrupt rather than correct genes, while the process can introduce new errors.
"Being able to use genome editing to treat genetic diseases requires, in most cases, ways to correct a DNA misspelling, not simply to disrupt a gene," Liu said.
That insight led his lab to develop base editing, which uses the Cas9 protein -- disabled so it can no longer cut both DNA strands -- to find a target DNA sequence and another enzyme to convert one letter to another -- for example, C to T or G to A.
Reversing the change -- from T to C or A to G -- was tougher. Liu's team overcame the challenge by engineering entirely new enzymes.
These base editors can now correct about 30 percent of the mutations that cause genetic diseases. The technology is already in at least 14 clinical trials.
In one of them, Beam Therapeutics -- which Liu co-founded -- announced it had treated patients of AATD, a rare genetic disorder affecting the lungs and liver, with a single drug infusion.
While traditional gene therapies often disrupt faulty genes or work around them, base editing repairs the mutation itself.
"This was the first time that humans have corrected a mutation that causes a genetic disease in a patient," Liu said.
- Cystic fibrosis hope -
Base editing, quickly dubbed "CRISPR 2.0," can't fix every mutation.
About 70 percent of the roughly 100,000 known disease-causing mutations remain out of its reach, including those caused by missing or extra letters.
To expand the toolkit, Liu's lab introduced prime editing in 2019 -- a method capable of replacing entire sections of faulty DNA with corrected sequences.
If CRISPR is like scissors that cut DNA, and base editors are like using a pencil to correct individual letters, then prime editing is the equivalent of a word processor's "find and replace" function.
Creating this tool required a series of breakthroughs Liu's team describes as "small miracles." The result is, he said, "the most versatile way we know of to edit the human genome."
Among the targets Liu and his team have already pursued with prime editing: cystic fibrosis, a common genetic disease usually caused by three missing DNA letters that causes thick mucus buildup in the lungs and digestive system.
Liu's lab has made much of its work freely accessible, sharing DNA blueprints through a nonprofit library used by tens of thousands of labs worldwide.
"The science we create -- which is ultimately funded by society, through governments and donors -- ultimately goes back to benefit society."
This year's Breakthrough Prize awards come at a fraught moment for US science, as President Donald Trump's government strips funding for institutions like the National Institutes of Health (NIH).
"The NIH is a treasure, not just for this country but for the world," said Liu. "Trying to dismantle the heart of what supports science in this country is like burning your seed corn."
P.Staeheli--VB